Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
The present invention provides protein kinase having one of the following structures (I), (II) or (III): or a stereoisomer, prodrug, tautomer or pharmaceutically acceptable salt thereof, wherein R, R 1 , R 2 and X are as defined herein. Compositions and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated conditions are also disclosed.
1. A compound having one of the following structures:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 , wherein the compound has the following structure:
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising the compound of claim 3 and a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising the compound of claim 4 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition comprising the compound of claim 7 and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising the compound of claim 8 and a pharmaceutically acceptable carrier.